Review says manufacturers capture a small share of medicine innovation value

A new systematic literature review in Applied Health Economics and Health Policy finds pharmaceutical manufacturers capture a minority of the net societal value created by innovative medicines, with a median producer surplus of 15% across 24 studies. The findings matter because they could shape debates over pricing, reimbursement, innovation incentives and patient access.

Why it matters: - Innovative medicines create economic value for patients, health systems and the broader economy, not just for manufacturers. - The review says understanding how that value is split can help inform policy choices that affect pricing, reimbursement, innovation incentives and patient access. - The authors say producer surplus evidence is not yet robust enough to support policy decisions on its own.

What happened: - The National Pharmaceutical Council and research collaborators published a systematic literature review in Applied Health Economics and Health Policy. - The paper, “Estimating the Share of Social Surplus Generated by Pharmaceutical Innovation Accruing to Manufacturers: A Systematic Literature Review,” examined how social surplus from innovative medicines is distributed. - The review analyzed 24 published studies on producer surplus in pharmaceuticals since April 2025. - The studies covered different diseases and drug classes and used inconsistent methods to measure social surplus.

The details: - Across 24 studies and 68 estimates, the median producer surplus was 15%. - By that measure, patients and society captured 85% of the social surplus through health gains and broader economic benefits. - Only six of the 24 studies estimated true manufacturer surplus. - Only one study used theoretically appropriate definitions of both consumer surplus and producer surplus. - Several studies used gross drug spending instead of manufacturer profit. - Some studies did not account for rebates and other supply-chain revenue. - Some studies left out broader societal benefits such as productivity gains. - The review says those methodological issues may cause existing literature to overstate manufacturers’ share.

Between the lines: - The findings push the conversation away from a simple claim that manufacturers capture “too much” value. - The more important question, the authors argue, is how value creation shapes incentives for future treatments. - The variation across studies suggests there is still no widely accepted standard for measuring producer surplus in this area. - That weakens the case for using any single estimate as a rule for reimbursement or health policy.

What's next: - Policymakers, payers and other stakeholders are likely to keep using producer surplus evidence as one input in broader value assessments. - The authors say the evidence can help evaluate frameworks that weigh current patient access against future therapeutic breakthroughs. - The review’s conclusions may add pressure for more consistent methods in future studies of pharmaceutical value.

The bottom line: - The review finds manufacturers receive a minority share of the social surplus generated by innovative medicines, but the measurement base is uneven enough that the authors urge caution before using any one estimate in policy decisions. - NPC says more information is available at NPC’s website and on LinkedIn and X.